新股消息 | 岸迈生物递表港交所 专注于开发治疗各类癌症和自身免疫性疾病的T细胞衔接器

Core Insights - Company is a clinical-stage biotechnology firm focused on developing T-cell engagers for cancer and autoimmune diseases, with a pipeline that includes three clinical candidates and several preclinical candidates [3][4] Pipeline Overview - Oncology pipeline includes three clinical-stage candidates: EMB-01 targeting EGFR/cMET for colorectal cancer, EMB-06 targeting BCMA/CD3 for multiple myeloma, and EMB-07 targeting ROR1/CD3 for lymphoma and solid tumors [3] - Immunology pipeline features EMB-06 as a key clinical candidate, along with two preclinical candidates [3] Technology Platforms - Company has developed three proprietary technology platforms: FIT-Ig, MAT-Fab, and T-FIT, aimed at overcoming limitations in traditional bispecific antibody development [4] Strategic Collaborations - Company has established multiple global licensing collaborations with a total transaction value exceeding $2.1 billion, ranking second globally in the T-cell engager field [4] - Collaboration with Almirall for the development of bispecific antibodies using the FIT-Ig platform, with Almirall exercising options on some FIT-Ig molecules [4] - Partnership with Vignette Bio, now acquired by Candid, to advance EMB-06 development outside of China, with a potential total transaction value of $635 million [5] Financial Performance - Company reported revenue of approximately RMB 459 million for the fiscal year 2024, with losses of RMB 595 million and RMB 48 million for the fiscal years 2023 and 2024, respectively [7][8] - Key financial metrics include a gross profit of RMB 456 million and significant R&D expenditures [8]